Post Reply
10741-10760 of 10899
shit , STI drops again, biosensors, huge sell down now as well, jia lat... 0.775 buy price now.... oh dear.. anyway, hold tight baby.
can TA experts advice? I am a FA person. I tried analysing the charts but am lost.
chances of them getting CE mark looks good. Think they r one of the best cos for heart stent now. small or medium but growing well. hope they get acquired in M&A deal in 2007. think at present price of 78.5c is a steal.
err... price now can buy up at 0.80, sien.. no worries la.. this guy is active one.....
hiya i am still stuck at the high......0.95 :( big frown.
vested 10 lots @ 0.815, cheers.
read an article on potential M&A activities in Asia and Biosensors appears to be a target. Co fundamentals appears good and all is now set upon obtaining the CE mark. Getting a bit tired of waiting but I guess no harm putting it in for long term appreciation. wats yr view?
some thing b4 CE?
Announcement at SGX-Net:
Biosensors announces positive results in on-going clinical trials for their BIOMATRIX stents including in Singapore.
The Registry results were presented by none other than Prof Koh Tian Hai, Director of Singapore National Heart Centre.
haha, what better "endorsement" than that!!!...guess any doubting local cardiologists will keep quiet now.
let see whether this will add weight for CEMark approval.
Biosensors announces positive results in on-going clinical trials for their BIOMATRIX stents including in Singapore.
The Registry results were presented by none other than Prof Koh Tian Hai, Director of Singapore National Heart Centre.
haha, what better "endorsement" than that!!!...guess any doubting local cardiologists will keep quiet now.
let see whether this will add weight for CEMark approval.
It is interesting to note that Biosensors has once again attempted to rally, with its 19 jan 07 high of 0.98 cents once again breaching above its 200 day mva. The last time it did this was in 06 dec 06, and that attempt did not succeed, resulting in a drop to a low of 0.845.
Nevertheless, the support around the 0.83-0.85 managed to hold, the last time. Baring any bad news, it seems unlikely for Biosensors to drop below 0.83- 0.85 level, having held this support for quite sometime now (approx 6 nths).
I always like to see a stock attempting to break above its 200 day mva and stay ABOVE there. As at today, its intr-day low of 0.925 touches the 200 mva and bounces off it.
Ideally, for a real trend reversal, Biosensors need to clear its resistance at the 0.98-1.01 level. If not, we are back to square one - with support at 0.82-0.85 level and resistance at 0.98-1.01 level.
http://remisiers.org/research/biosensors-070119-oir.pdf
read the lastest research which will cause price to rise.
Quoted from Shareinvestor :::
Singapore, 5 January 2007 ? Biosensors International Group, Ltd. (?Biosensors? or the ?Company?,
Bloomberg BIG SP) announced today that it has completed its convertible note financing, previously
announced on 23 November 2006, with the closing of the third and final tranche in the amount of
US$15 million and the issuance of convertible and unsubordinated 3.95% three-year notes. The
closing of this final tranche, placed with Silicon Valley-based Three Arch Partners, increases the total
raised in the financing to US$45 million.
Three Arch Partners, based in Portola Valley, California, is one of the pre-eminent healthcare
investment companies in the United States having made more than US$1 billion in venture,
development and growth stage investments in more than eighty medical technology companies since
its inception in 1993.
Mr. Yoh-Chie Lu, Chairman and CEO of Biosensors commented: ?This successful financing is an
important milestone for Biosensors as we prepare for the launch of our flagship BioMatrix
® drugeluting stent as well as accelerate our other ongoing research and development programs.
Participants in the financing include Granite Global, Evolution Capital and now Three Arch Partners
which specialize in investments in healthcare and medical technology in the US. Three Arch Partners
is a premier name in the private equity business with a strong track record of providing healthcare
companies with access to relevant clinical, business and capital resources?.
Mr. Mark Wan of Three Arch Partners commented: "Biosensors has the technology and the
opportunity to become a technology leader in the drug-eluting stent market, as its technologies
continue to receive strong validation by leading cardiologists. The Company?s technological
achievements in developing polymer-free and biodegradable stent platforms underlies its prospects to
emerge as a key player in this US$6 billion drug-eluting stent market. Three Arch Partners is very
pleased to be a part of this exciting company and I look forward to be able to lend my expertise and
the resources of our organization where possible.?
Even Genting's price can more than double despite the fact that earnings will only kick in about seven years later. The bottom line is that the mrk is flushed with all sort of funds; be it long term, short term, speculative and private equity etc. If indeed the CE mark is expected in this quarter, shouldn't one be accumulating this stock for its accent to heaven? Think the risk reward ratio is good enough to garner some punts on this counter.
Bloomberg BIG SP) announced today that it has completed its convertible note financing, previously
announced on 23 November 2006, with the closing of the third and final tranche in the amount of
US$15 million and the issuance of convertible and unsubordinated 3.95% three-year notes. The
closing of this final tranche, placed with Silicon Valley-based Three Arch Partners, increases the total
raised in the financing to US$45 million.
Three Arch Partners, based in Portola Valley, California, is one of the pre-eminent healthcare
investment companies in the United States having made more than US$1 billion in venture,
development and growth stage investments in more than eighty medical technology companies since
its inception in 1993.
Mr. Yoh-Chie Lu, Chairman and CEO of Biosensors commented: ?This successful financing is an
important milestone for Biosensors as we prepare for the launch of our flagship BioMatrix
® drugeluting stent as well as accelerate our other ongoing research and development programs.
Participants in the financing include Granite Global, Evolution Capital and now Three Arch Partners
which specialize in investments in healthcare and medical technology in the US. Three Arch Partners
is a premier name in the private equity business with a strong track record of providing healthcare
companies with access to relevant clinical, business and capital resources?.
Mr. Mark Wan of Three Arch Partners commented: "Biosensors has the technology and the
opportunity to become a technology leader in the drug-eluting stent market, as its technologies
continue to receive strong validation by leading cardiologists. The Company?s technological
achievements in developing polymer-free and biodegradable stent platforms underlies its prospects to
emerge as a key player in this US$6 billion drug-eluting stent market. Three Arch Partners is very
pleased to be a part of this exciting company and I look forward to be able to lend my expertise and
the resources of our organization where possible.?
Even Genting's price can more than double despite the fact that earnings will only kick in about seven years later. The bottom line is that the mrk is flushed with all sort of funds; be it long term, short term, speculative and private equity etc. If indeed the CE mark is expected in this quarter, shouldn't one be accumulating this stock for its accent to heaven? Think the risk reward ratio is good enough to garner some punts on this counter.
CIMB
Biosensors International (S$0.88) - Not Conor's twin
Recent speculative interest in Biosensors following Johnson & Johnson's (J&J) acquisition
of Conor is unjustified. We argue that J&J's acquisition of Conor had little to do with
biodegradable polymer and was actually driven by Conor's strong product pipeline and
unique controlled drug delivery technology. Biosensors now faces a stronger competitor.
We also find that recent 2-day USFDA panel meeting results appear to favor incumbent
DES players (J&J and Boston Scientific). Our probability-based DCF valuation (excludes
buyout scenario) suggests that current valuation implies a premature certainty of
Biosensors capturing a 10% global market share. Maintain Underperform with
unchanged target price of S$0.76.
Thanks. Hope you had a good holiday. Merry X'mas and Happy New Year!
Hi Livermore,
Looks to be on a downtrend now
Looks to be on a downtrend now
Hi Singaporegal and other TA gurus,
Any comments on Biosensors?
good analysis
Whether Biosensors will become a take-over target really depends on whether its technology can add-value to these companies.
I dont really know whether its technology is superior to other companies or not. However, I can try to summarise, what I think is good about its technology, and what is not so good, and for you guys to draw your own conclusion.
Stent Design - in my mind, so so only - nothing spectacular
Biolimus Drug - created by Biosensors - supposed to be as good as Sirolimus. Can be potentially a winner, once there is acceptance - one by the CE mark approval, 2nd, and more importantly by the FDA, as under the FDA, stringent tests on the safety needs to be carried out on healthy patients, involving single dose and mulitple doses.
Biodegradable polymer - potentially a winner, used in combination with the biolimus drug.
Having multiple partners, like Terumo, Xtent, Devax - potentially a good move, as it will widen their attractiveness, with the proviso that their drug has been approved for use by FDA (everything hinges on that)
I believe that the single drug dosage on patients has been carried out and it seems to be successful (my impression from the conf call).
Lack of large scale clinical trials - this is their main weakness - so far only a 120 clinical patient trial -Stealth I, and the 240 patient Nobori trial (phase I completed).
All the major players have clinical trials numbering into thousands of patients, even Conors have 500 or more patients, collectively.
Time is of the essence - Biosensors is going to conduct 2 major trials involving 1500 or more patients soon. IF newer and better technology comes along, in the distant future, then the value of Biosensros may deteriorate.
Biosensor is also going to conduct clinical trials on the 'Freedom stent' - a new design that is 'polymer-free', and uses the Biolimus drug on rough microporous surface to control drug release, instead of a polymer. They also have done some animal testing on bio-degradable stent (ie stent can be degraded away), and have some success with it
The good news is that so far, I have not seen any other new companies doing research on bio-degradable polymers, new drugs, etc. Although Abbot lab (I believe) did a first-in man clinical trial on a bio-degradable stent (ie the stent can dissolve), but they are using the Biosensor's biodegradable polymer, in this trial. I believe, that this will be quite some time before it gains momentum.
investor,
Good and insightful post. You must be medically trained or involved in this industry?
Perhap Biosensors may become a takeover target once it receives its CE mark?
My analysis of the FDA panel recommendations are as follows. The only concrete thing that the FDA is doing is that it is advising DES patients to take their plavix pills for up to one yr. or longer.
Thus, the fear of the FDA doing away with the DES or severely restricting the sale of the DES has not materalised. THe recommendation of the panel to expand the clinical trials to include stent thrombosis will probably be resisted quite agressively by major industry players, as stent thrombosis is a long term problem, stretching out to 2-5 yrs or even longer, and it is probably impractical to do so.
In fact, there is a silver lining for next generation players like Conors, Biosensors, as their technology is supposed to do away with the most likely cause of the stent thrombosis, which is the 'polymer'. That may be one of the reasons, why J & J bought over Conors, as they will have ready technology, with bio-degradable polymer, that has been CE mark approved, and they can built on that, instead of starting the research on biodegradable polymer from scratch.
Having said that, the offical anouncement by J & J,on why they bought conors was that they like their stent design, which allows for mulitple drug delivery.
no wonder going down hill at the moment